Avadel Pharmaceuticals plc

Historical 13F Holders

Symbol
AVDL
CUSIP
05337M104
All holders as of
Q2 2026
Type
Equity
Class
SPONSORED ADR
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 05337M104 since 12/18/2024, largest first.

Filer % of Class Filed
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Jeffrey L. Gendell 13G/A
4.9% 2/6/2026
Event 12/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 1.00 $16.00
2026 Q1 1 1.00 $16.00
2025 Q4 2 600 k $12.9 M
2025 Q3 3 738 k $11.3 M
2025 Q2 4 738 k $6.53 M
2025 Q1 3 738 k $5.77 M
2024 Q4 3 737 k $7.75 M
2024 Q3 5 1.07 M $14.0 M
2024 Q2 10 7.03 M $98.8 M
2024 Q1 136 69.5 M $1.17 B
2023 Q4 130 57.8 M $817 M
2023 Q3 112 54.4 M $559 M
2023 Q2 113 52.0 M $858 M
2023 Q1 103 48.6 M $444 M
2022 Q4 100 33.5 M $240 M
2022 Q3 89 31.4 M $157 M
2022 Q2 92 33.7 M $82.4 M
2022 Q1 97 35.9 M $252 M
2021 Q4 104 35.2 M $284 M
2021 Q3 96 32.1 M $314 M
2021 Q2 92 32.6 M $219 M
2021 Q1 93 32.6 M $295 M
2020 Q4 96 32.2 M $215 M
2020 Q3 88 31.5 M $159 M
2020 Q2 89 36.3 M $294 M
2020 Q1 78 26.9 M $211 M
2019 Q4 51 18.4 M $139 M
2019 Q3 51 19.4 M $80.6 M
2019 Q2 51 19.6 M $56.6 M
2019 Q1 50 19.6 M $28.2 M
2018 Q4 62 19.8 M $51.1 M
2018 Q3 72 20.2 M $88.7 M
2018 Q2 83 21.2 M $130 M
2018 Q1 90 27.2 M $198 M
2017 Q4 86 26.4 M $217 M
2017 Q3 85 27.2 M $285 M
2017 Q2 79 27.8 M $306 M
2017 Q1 76 29.2 M $283 M
2016 Q4 6 4.30 M $44.7 M